Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma
Abstract
:1. Introduction
2. Results
2.1. ATO/Lena Enhances Survival and Reduces Lymphomatous Effusions in PEL Mice
2.2. ATO/Lena Inhibits Proliferation and Downregulates KSHV Latent Proteins in Ex Vivo Ascites-Derived PEL Cells
2.3. ATO/Lena Decreases Tumor Burden through Inhibiting Autocrine Cytokines in Ex Vivo Ascites-Derived PEL Cells
2.4. ATO/Lena Induces KSHV Lytic Gene Expression in Ex Vivo Ascites-Derived PEL Cells
2.5. ATO/Lena Induces Apoptosis in Ex Vivo Ascites-Derived PEL Cells
2.6. ATO/Lena Inhibits VEGF-Dependent Endothelial Cells Tube Formation
2.7. ATO/Lena Decreases Organ Infiltration and Downregulates Latent KSHV Proteins and Cytokine Expression In Vivo
3. Discussion
4. Materials and Methods
4.1. Cells, Mice, and Treatment
4.2. Ex Vivo Cell Culture and Analysis
4.3. Gene Expression Studies
4.4. Protein Expression Studies
4.5. Immunofluorescence Assay
4.6. Matrigel-Induced Capillary Tube Formation
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Katano, H. Pathological Features of Kaposi’s Sarcoma-Associated Herpesvirus Infection. In Human Herpesviruses; Kawaguchi, Y., Mori, Y., Kimura, H., Eds.; Springer: Singapore, 2018; pp. 357–376. [Google Scholar]
- Shimada, K.; Hayakawa, F.; Kiyoi, H. Biology and management of primary effusion lymphoma. Blood 2018, 132, 1879–1888. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, Y.; Cesarman, E.; Pessin, M.; Lee, F.; Culpepper, J.; Knowles, D.; Moore, P. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266, 1865–1869. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cesarman, E.; Chang, Y.; Moore, P.S.; Said, J.W.; Knowles, D.M. Kaposi’s Sarcoma–Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity–Based Lymphomas. N. Engl. J. Med. 1995, 332, 1186–1191. [Google Scholar] [CrossRef] [PubMed]
- Minhas, V.; Wood, C. Epidemiology and Transmission of Kaposi’s Sarcoma-Associated Herpesvirus. Viruses 2014, 6, 4178–4194. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.B.; Rahemtullah, A.; Hochberg, E. Primary effusion lymphoma. Oncologist 2007, 12, 569–576. [Google Scholar] [CrossRef] [Green Version]
- Boulanger, E.; Hermine, O.; Fermand, J.-P.; Radford-Weiss, I.; Brousse, N.; Meignin, V.; Gessain, A. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-negative elderly patients. Am. J. Hematol. 2004, 76, 88–91. [Google Scholar] [CrossRef]
- Boulanger, E.; Afonso, P.V.; Yahiaoui, Y.; Adle-Biassette, H.; Gabarre, J.; Agbalika, F. Human Herpesvirus-8 (HHV-8)-Associated Primary Effusion Lymphoma in two Renal Transplant Recipients Receiving Rapamycin. Am. J. Transplant. 2008, 8, 707–710. [Google Scholar] [CrossRef]
- Sasaki, Y.; Isegawa, T.; Shimabukuro, A.; Yonaha, T.; Yonaha, H. Primary Effusion Lymphoma in an Elderly HIV-Negative Patient with Hemodialysis: Importance of Evaluation for Pleural Effusion in Patients Receiving Hemodialysis. Case Rep. Nephrol. Dial. 2014, 4, 95–102. [Google Scholar] [CrossRef]
- Said, J.W.; Tasaka, T.; Takeuchi, S.; Asou, H.; de Vos, S.; Cesarman, E.; Knowles, D.M.; Koeffler, H. Primary effusion lymphoma in women: Report of two cases of Kaposi’s sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 1996, 88, 3124–3128. [Google Scholar] [CrossRef]
- Arora, N.; Gupta, A.; Sadeghi, N. Primary effusion lymphoma: Current concepts and management. Curr. Opin. Pulm. Med. 2017, 23, 365–370. [Google Scholar] [CrossRef] [PubMed]
- Medeiros, B.C.; Maness, L.J.; Bauer, F.A.; Ross, J.W.; Kapur, D. Unusual presentation of “extracavitary” primary effusion lymphoma in previously unknown HIV disease. Conn. Med. 2000, 64, 591–594. [Google Scholar] [PubMed]
- Chadburn, A.; Hyjek, E.; Mathew, S.; Cesarman, E.; Said, J.; Knowles, D.M. KSHV-Positive Solid Lymphomas Represent an Extra-Cavitary Variant of Primary Effusion Lymphoma. Am. J. Surg. Pathol. 2004, 28, 1401–1416. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, L.D. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematol. Am. Soc. Hematol. Educ. Program. 2013, 2013, 103–108. [Google Scholar] [CrossRef]
- Carbone, A.; Gloghini, A. KSHV/HHV8-associated lymphomas. Br. J. Haematol. 2008, 140, 13–24. [Google Scholar] [CrossRef] [PubMed]
- Said, J. Kaposi’s sarcoma-associated herpesvirus (KSHV): A new viral pathogen associated with Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. West J. Med. 1997, 167, 37–38. [Google Scholar]
- Wen, K.W.; Damania, B. Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Lett. 2010, 289, 140–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kedes, D.H.; Lagunoff, M.; Renne, R.; Ganem, D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi’s sarcoma-associated herpesvirus. J. Clin. Investig. 1997, 100, 2606–2610. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Uppal, T.; Banerjee, S.; Sun, Z.; Verma, S.C.; Robertson, E.S. KSHV LANA--the master regulator of KSHV latency. Viruses 2014, 6, 4961–4998. [Google Scholar] [CrossRef] [Green Version]
- Schulz, T.F.; Cesarman, E. Kaposi Sarcoma-associated Herpesvirus: Mechanisms of oncogenesis. Curr. Opin. Virol. 2015, 14, 116–128. [Google Scholar] [CrossRef]
- Yan, L.; Majerciak, V.; Zheng, Z.M.; Lan, K. Towards Better Understanding of KSHV Life Cycle: From Transcription and Posttranscriptional Regulations to Pathogenesis. Virol. Sin. 2019, 34, 135–161. [Google Scholar] [CrossRef] [Green Version]
- Patel, R.M.; Goldblum, J.R.; Hsi, E.D. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod. Pathol. 2004, 17, 456–460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fukumoto, H.; Kanno, T.; Hasegawa, H.; Katano, H. Pathology of Kaposi’s Sarcoma-Associated Herpesvirus Infection. Front. Microbiol. 2011, 2, 175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cai, Q.L.; Knight, J.S.; Verma, S.C.; Zald, P.; Robertson, E.S. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2006, 2, e116. [Google Scholar] [CrossRef] [PubMed]
- DeCotiis, J.L.; Lukac, D.M. KSHV and the Role of Notch Receptor Dysregulation in Disease Progression. Pathogens 2017, 6, 34. [Google Scholar] [CrossRef]
- Wies, E.; Mori, Y.; Hahn, A.; Kremmer, E.; Stürzl, M.; Fleckenstein, B.; Neipel, F. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008, 111, 320–327. [Google Scholar] [CrossRef]
- Muñoz-Fontela, C.; Marcos-Villar, L.; Hernandez, F.; Gallego, P.; Rodriguez, E.; Arroyo, J.; Gao, S.J.; Avila, J.; Rivas, C. Induction of paclitaxel resistance by the Kaposi’s sarcoma-associated herpesvirus latent protein LANA2. J. Virol. 2008, 82, 1518–1525. [Google Scholar] [CrossRef] [Green Version]
- Godden-Kent, D.; Talbot, S.J.; Boshoff, C.; Chang, Y.; Moore, P.; Weiss, R.A.; Mittnacht, S. The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J. Virol. 1997, 71, 4193–4198. [Google Scholar] [CrossRef] [Green Version]
- Guasparri, I.; Keller, S.A.; Cesarman, E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 2004, 199, 993–1003. [Google Scholar] [CrossRef]
- Bélanger, C.; Gravel, A.; Tomoiu, A.; Janelle, M.E.; Gosselin, J.; Tremblay, M.J.; Flamand, L. Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J. Hum. Virol. 2001, 4, 62–73. [Google Scholar]
- Thome, M.; Schneider, P.; Hofmann, K.; Fickenscher, H.; Meinl, E.; Neipel, F.; Mattmann, C.; Burns, K.; Bodmer, J.L.; Schröter, M.; et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386, 517–521. [Google Scholar] [CrossRef] [Green Version]
- Sun, Q.; Zachariah, S.; Chaudhary, P.M. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J. Biol. Chem. 2003, 278, 52437–52445. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Field, N.; Low, W.; Daniels, M.; Howell, S.; Daviet, L.; Boshoff, C.; Collins, M. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell Sci. 2003, 116 Pt 18, 3721–3728. [Google Scholar] [CrossRef] [Green Version]
- Chaudhary, P.M.; Jasmin, A.; Eby, M.T.; Hood, L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 1999, 18, 5738–5746. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Keller, S.A.; Hernandez-Hopkins, D.; Vider, J.; Ponomarev, V.; Hyjek, E.; Schattner, E.J.; Cesarman, E. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006, 107, 3295–3302. [Google Scholar] [CrossRef] [PubMed]
- Foussat, A.; Wijdenes, J.; Bouchet, L.; Gaidano, G.; Neipel, F.; Balabanian, K.; Galanaud, P.; Couderc, J.; Emilie, D. Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes. Eur. Cytokine Netw. 1999, 10, 501–508. [Google Scholar] [PubMed]
- Jones, K.D.; Aoki, Y.; Chang, Y.; Moore, P.S.; Yarchoan, R.; Tosato, G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi’s sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999, 94, 2871–2879. [Google Scholar] [CrossRef]
- Goto, H.; Kudo, E.; Kariya, R.; Taura, M.; Katano, H.; Okada, S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J. Cancer Res. Clin. Oncol. 2015, 141, 465–474. [Google Scholar] [CrossRef]
- Okada, S.; Goto, H.; Yotsumoto, M. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis. Res. 2014, 3, 65–74. [Google Scholar] [CrossRef] [Green Version]
- Narkhede, M.; Arora, S.; Ujjani, C. Primary effusion lymphoma: Current perspectives. Onco Targets Ther. 2018, 11, 3747–3754. [Google Scholar] [CrossRef] [Green Version]
- Li, S.; Bai, L.; Dong, J.; Sun, R.; Lan, K. Kaposi’s Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology. Adv. Exp. Med. Biol. 2017, 1018, 91–127. [Google Scholar] [CrossRef]
- Dimopoulos, M.; Spencer, A.; Attal, M.; Prince, H.M.; Harousseau, J.L.; Dmoszynska, A.; San Miguel, J.; Hellmann, A.; Facon, T.; Foà, R.; et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 2007, 357, 2123–2132. [Google Scholar] [CrossRef] [Green Version]
- Shortt, J.; Hsu, A.K.; Johnstone, R.W. Thalidomide-analogue biology: Immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013, 32, 4191–4202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flowers, C.R.; Leonard, J.P.; Fowler, N.H. Lenalidomide in follicular lymphoma. Blood 2020, 135, 2133–2136. [Google Scholar] [CrossRef] [PubMed]
- Hernandez-Ilizaliturri, F.J.; Batoo, S.A. The emerging role of lenalidomide in the management of lymphoid malignancies. Ther. Adv. Hematol. 2011, 2, 45–53. [Google Scholar] [CrossRef] [PubMed]
- Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P.M. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 2016, 35, 1797–1810. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davis, D.A.; Mishra, S.; Anagho, H.A.; Aisabor, A.I.; Shrestha, P.; Wang, V.; Takamatsu, Y.; Maeda, K.; Mitsuya, H.; Zeldis, J.B.; et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget 2017, 8, 50342–50358. [Google Scholar] [CrossRef] [Green Version]
- Antar, A.; El Hajj, H.; Jabbour, M.; Khalifeh, I.; El-Merhi, F.; Mahfouz, R.; Bazarbachi, A. Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: Case report and review of literature. Blood Cancer J. 2014, 4, e190. [Google Scholar] [CrossRef] [Green Version]
- Ghavamzadeh, A.; Alimoghaddam, K.; Rostami, S.; Ghaffari, S.H.; Jahani, M.; Iravani, M.; Mousavi, S.A.; Bahar, B.; Jalili, M. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J. Clin. Oncol. 2011, 29, 2753–2757. [Google Scholar] [CrossRef]
- Powell, B.L.; Moser, B.; Stock, W.; Gallagher, R.E.; Willman, C.L.; Stone, R.M.; Rowe, J.M.; Coutre, S.; Feusner, J.H.; Gregory, J.; et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116, 3751–3757. [Google Scholar] [CrossRef] [Green Version]
- Kchour, G.; Rezaee, R.; Farid, R.; Ghantous, A.; Rafatpanah, H.; Tarhini, M.; Kooshyar, M.M.; El Hajj, H.; Berry, F.; Mortada, M.; et al. The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology 2013, 10, 91. [Google Scholar] [CrossRef] [Green Version]
- Miller, W.H., Jr.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62, 3893–3903. [Google Scholar] [PubMed]
- Abou-Merhi, R.; Khoriaty, R.; Arnoult, D.; El Hajj, H.; Dbouk, H.; Munier, S.; El-Sabban, M.E.; Hermine, O.; Gessain, A.; de Thé, H.; et al. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells. Leukemia 2007, 21, 1792–1801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Hajj, H.; Ali, J.; Ghantous, A.; Hodroj, D.; Daher, A.; Zibara, K.; Journo, C.; Otrock, Z.; Zaatari, G.; Mahieux, R.; et al. Combination of arsenic and interferon-alpha inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. PLoS ONE 2013, 8, e79474. [Google Scholar] [CrossRef] [PubMed]
- Brown, H.J.; Song, M.J.; Deng, H.; Wu, T.T.; Cheng, G.; Sun, R. NF-kappaB inhibits gammaherpesvirus lytic replication. J. Virol. 2003, 77, 8532–8540. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grossmann, C.; Ganem, D. Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology 2008, 375, 94–102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Keller, S.A.; Schattner, E.J.; Cesarman, E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000, 96, 2537–2542. [Google Scholar] [CrossRef]
- Buesche, G.; Dieck, S.; Giagounidis, A.; Bock, O.; Wilkens, L.; Schlegelberger, B.; Knight, R.; Bennett, J.; Aul, C.; Kreipe, H.H. Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease. Blood 2005, 106, 372. [Google Scholar] [CrossRef]
- Kotla, V.; Goel, S.; Nischal, S.; Heuck, C.; Vivek, K.; Das, B.; Verma, A. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2009, 2, 36. [Google Scholar] [CrossRef] [Green Version]
- Aoki, Y.; Tosato, G. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk. Lymphoma 2001, 41, 229–237. [Google Scholar] [CrossRef]
- Haddad, L.; El Hajj, H.; Abou-Merhi, R.; Kfoury, Y.; Mahieux, R.; El-Sabban, M.; Bazarbachi, A. KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. Leukemia 2008, 22, 826–834. [Google Scholar] [CrossRef] [Green Version]
- El Hajj, H.; Dassouki, Z.; Berthier, C.; Raffoux, E.; Ades, L.; Legrand, O.; Hleihel, R.; Sahin, U.; Tawil, N.; Salameh, A.; et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood 2015, 125, 3447–3454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martelli, M.P.; Gionfriddo, I.; Mezzasoma, F.; Milano, F.; Pierangeli, S.; Mulas, F.; Pacini, R.; Tabarrini, A.; Pettirossi, V.; Rossi, R.; et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood 2015, 125, 3455–3465. [Google Scholar] [CrossRef] [PubMed]
- Bazarbachi, A.; El-Sabban, M.E.; Nasr, R.; Quignon, F.; Awaraji, C.; Kersual, J.; Dianoux, L.; Zermati, Y.; Haidar, J.H.; Hermine, O.; et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93, 278–283. [Google Scholar] [CrossRef] [PubMed]
- El Hajj, H.; El-Sabban, M.; Hasegawa, H.; Zaatari, G.; Ablain, J.; Saab, S.T.; Janin, A.; Mahfouz, R.; Nasr, R.; Kfoury, Y.; et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J. Exp. Med. 2010, 207, 2785–2792. [Google Scholar] [CrossRef]
- Kchour, G.; Tarhini, M.; Kooshyar, M.M.; El Hajj, H.; Wattel, E.; Mahmoudi, M.; Hatoum, H.; Rahimi, H.; Maleki, M.; Rafatpanah, H.; et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113, 6528–6532. [Google Scholar] [CrossRef]
- Wang, H.; Chen, X.; Eksioglu, E.; Zhou, J.; Fortenbery, N.; Djeu, J.; List, A.; Wei, S. Lenalidomide and Arsenic Trioxide Have Independent Non-Interfering Effects When Used in Combination on Myeloma Cell Lines in Vitro. J. Cancer Ther. 2013, 4, 787–796. [Google Scholar] [CrossRef] [Green Version]
- Jian, Y.; Gao, W.; Geng, C.; Zhou, H.; Leng, Y.; Li, Y.; Chen, W. Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol. Lett. 2017, 14, 3243–3248. [Google Scholar] [CrossRef] [Green Version]
- Pearce, M.; Matsumura, S.; Wilson, A.C. Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi’s sarcoma-associated herpesvirus originate from a common promoter. J. Virol. 2005, 79, 14457–14464. [Google Scholar] [CrossRef] [Green Version]
- Low, W.; Harries, M.; Ye, H.; Du, M.Q.; Boshoff, C.; Collins, M. Internal ribosome entry site regulates translation of Kaposi’s sarcoma-associated herpesvirus FLICE inhibitory protein. J. Virol. 2001, 75, 2938–2945. [Google Scholar] [CrossRef] [Green Version]
- Ye, F.; Zhou, F.; Bedolla, R.G.; Jones, T.; Lei, X.; Kang, T.; Guadalupe, M.; Gao, S.J. Reactive oxygen species hydrogen peroxide mediates Kaposi’s sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011, 7, e1002054. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Feng, J.; Sun, R. Oxidative Stress Induces Reactivation of Kaposi’s Sarcoma-Associated Herpesvirus and Death of Primary Effusion Lymphoma Cells. J. Virol. 2011, 85, 715–724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sebastian, S.; Zhu, Y.X.; Braggio, E.; Shi, C.-X.; Panchabhai, S.C.; Van Wier, S.A.; Ahmann, G.J.; Chesi, M.; Bergsagel, P.L.; Stewart, A.K.; et al. Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity. Blood 2017, 129, 991–1007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, Y.; Li, J.; Lou, B.; Wu, R.; Wang, G.; Lu, C.; Wang, H.; Pi, J.; Xu, Y. The Role of Reactive Oxygen Species in Arsenic Toxicity. Biomolecules 2020, 10, 240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hussain, A.R.; Ahmed, S.O.; Ahmed, M.; Khan, O.S.; Al Abdulmohsen, S.; Platanias, L.C.; Al-Kuraya, K.S.; Uddin, S. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS ONE 2012, 7, e39945. [Google Scholar] [CrossRef]
- An, J.; Sun, Y.; Sun, R.; Rettig, M.B. Kaposi’s sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: The role of the NF-kappaB and JNK/AP1 pathways. Oncogene 2003, 22, 3371–3385. [Google Scholar] [CrossRef] [Green Version]
- Lurain, K.; Polizzotto, M.N.; Aleman, K.; Bhutani, M.; Wyvill, K.M.; Gonçalves, P.H.; Ramaswami, R.; Marshall, V.A.; Miley, W.; Steinberg, S.M.; et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood 2019, 133, 1753–1761. [Google Scholar] [CrossRef] [Green Version]
- Zhou, F.; Shimoda, M.; Olney, L.; Lyu, Y.; Tran, K.; Jiang, G.; Nakano, K.; Davis, R.R.; Tepper, C.G.; Maverakis, E.; et al. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. Mol. Cancer Ther. 2017, 16, 2627–2638. [Google Scholar] [CrossRef] [Green Version]
- Renne, R.; Zhong, W.; Herndier, B.; McGrath, M.; Abbey, N.; Kedes, D.; Ganem, D. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 1996, 2, 342–346. [Google Scholar] [CrossRef]
- Arvanitakis, L.; Mesri, E.A.; Nador, R.G.; Said, J.W.; Asch, A.S.; Knowles, D.M.; Cesarman, E. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 1996, 88, 2648–2654. [Google Scholar] [CrossRef] [Green Version]
- Wu, W.; Rochford, R.; Toomey, L.; Harrington, W., Jr.; Feuer, G. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk. Res. 2005, 29, 545–555. [Google Scholar] [CrossRef]
- Tomayko, M.M.; Reynolds, C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharm. 1989, 24, 148–154. [Google Scholar] [CrossRef] [PubMed]
- Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3, 1101–1108. [Google Scholar] [CrossRef]
- Albini, A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol. Oncol. Res. 1998, 4, 230–241. [Google Scholar] [CrossRef] [PubMed]
- Ghayad, S.E.; Rammal, G.; Ghamloush, F.; Basma, H.; Nasr, R.; Diab-Assaf, M.; Chelala, C.; Saab, R. Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts. Sci. Rep. 2016, 6, 37088. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moodad, S.; El Hajj, R.; Hleihel, R.; Hajjar, L.; Tawil, N.; Karam, M.; Hamie, M.; Abou Merhi, R.; El Sabban, M.; El Hajj, H. Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma. Cancers 2020, 12, 2483. https://doi.org/10.3390/cancers12092483
Moodad S, El Hajj R, Hleihel R, Hajjar L, Tawil N, Karam M, Hamie M, Abou Merhi R, El Sabban M, El Hajj H. Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma. Cancers. 2020; 12(9):2483. https://doi.org/10.3390/cancers12092483
Chicago/Turabian StyleMoodad, Sara, Rana El Hajj, Rita Hleihel, Layal Hajjar, Nadim Tawil, Martin Karam, Maguy Hamie, Raghida Abou Merhi, Marwan El Sabban, and Hiba El Hajj. 2020. "Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma" Cancers 12, no. 9: 2483. https://doi.org/10.3390/cancers12092483